Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma

PURPOSE: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with camrelizumab (hereafter, TACE-camrelizumab) in the treatment of patients with recurrent hepatocellular carcinoma (R-HCC) after curative resection. PATIENTS AND METHODS: R-HCC patients who underwent T...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yusheng, Ren, Yanqiao, Chen, Lei, Sun, Tao, Zhang, Weihua, Sun, Bo, Zhu, Licheng, Xiong, Fu, Zheng, Chuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/
https://www.ncbi.nlm.nih.gov/pubmed/35287627
http://dx.doi.org/10.1186/s12885-022-09325-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922827/
https://www.ncbi.nlm.nih.gov/pubmed/35287627
http://dx.doi.org/10.1186/s12885-022-09325-6

Ejemplares similares